Topotecan as a Continuous Infusion over 14 Days in Recurrent Ovarian Cancer Patients

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1267-1269

  Denschlag, Dominik ^a,b   Watermann, D ^a   Horig K ^a   Kissel, C ^a   Tempfer, C ^a   Gitsch, G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Ovarian cancer; Topotecan

Indexed keywords

CYTOTOXIC AGENT; HYCAMPTIN; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; ECHOGRAPHY; FEMALE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PILOT PROJECTS; TOPOTECAN;

EID: 2442449503     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Crayford TJ, Campbell S, Bourne TH, Rawson HJ and Collins WP: Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355(9209): 1060-1063, 2000.
2. Smith H: Clinical management of ovarian cancer. N Engl J Med 345(2): 152-15a, 2001.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334(1): 1-6, 1996.
4. McGuire WP III: Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 21(10 Suppl): 133-5, 2003.
5. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Nat Cancer Inst 92(9): 699-708, 2000.
6. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361(9376): 2235-2242, 2003.
7. ten Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15(6): 2183-2193, 1997.
8. Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS et al: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15(3): 1087-1093, 1997.
9. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14): 3312-3322, 2001.
10. McGuire WP, Blessing JA, Bookman MA, Lentz SS and Dunton CJ: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 18(5): 1062-1067, 2000.
11. Swisher EM, Mutch DG, Rader JS, Elbendary A and Herzog TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecologic Oncology 66(3): 480-486, 1997.
12. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12(3): 553-559, 1994.
13. Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R et al: Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 17(8): 2553-2561, 1999.
14. Elkas JC, Holschneider CH, Katz B, Li AJ, Louie R, McGonigle KF et al: The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J Gynecol Cancer 13(2): 138-141, 2003.
15. Gore M, Rustin G, Schuller J, Lane SR, Hearn S, Beckman RA et al: Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Brit J Cancer 84(8): 1043-1046, 2001.
16. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G et al: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16(6): 2233-2237, 1998.